abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Engaging African ancestry participants in SLE clinical trials

Author information

Anjorin A1, Lipsky P2. Lupus Sci Med. 2018 Dec 11;5(1):e000297. doi: 10.1136/lupus-2018-000297. eCollection 2018.


Author information 1 RILITE Research Institute, and University of Virginia, Charlottesville, Virginia, USA. 2 RILITE Research Institute, Charlottesville, Virginia, USA.

Abstract SLE is a complex autoimmune disease with genetic and clinical differences between patients that appear to reside along ancestral lines. Over the last 20 years, a preponderance of evidence has shown that SLE is more common and severe in minority populations, particularly in African ancestry (AA) women. However, in clinical trials for new therapies of SLE, AA is often under-represented. Without enrolling sufficient AA participants, it is difficult to ascertain the safety and efficacy of new potential therapies among individuals with SLE of different ancestries. Although enrolling minority populations in clinical trials has been a significant challenge for many reasons, the various stakeholders involved in clinical research could act within their own realms to develop new paradigms and policies to bolster the inclusion of AA in the development of new therapies.